Open and Recruiting
Clinical Trials

• 

  A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ZW251 in Patients with Advanced Solid Tumors

  https://clinicaltrials.gov/study/NCT07164313?term=ZW251&rank=1

  • Sponsor

    Zymeworks

  • Trial ID

    NCT07164313

  • Study Details

    A Study of ZW251 in Participants With Advanced Solid Tumors

  • Study Url

    https://clinicaltrials.gov/study/NCT07164313?term=ZW251&rank=1

  • Cancer Type

    Advanced solid tumors

  • Status

    Recruiting

  Brief Summary

  A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors, Including Hepatocellular Carcinoma

• 

  A Phase 1a/b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C137, an Antibody-Drug Conjugate Targeting FGFR2b, in Patients With Advanced Solid Tumors

  Study Details | NCT06625593 | A First-in-Human Study of BG-C137, an Anti-FGFR2b Antibody Drug Conjugate, in Participants With Advanced Solid Tumors | ClinicalTrials.gov

  • Sponsor

    BeOne Medicines, formerly BeiGene

  • Trial ID

    NCT06625593

  • Study Details

    A First-in-Human Study of BG-C137, an Anti-FGFR2b Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

  • Study Url

    https://clinicaltrials.gov/study/NCT06625593?term=BG-C137&rank=1

  • Cancer Type

    Advanced solid tumors

  • Status

    Preparing

• 

  A Phase 1 First-in-human Study of BMS-986500 as Monotherapy in Advanced Solid Tumors and as Combination Therapy in CDK4/6 Inhibitor Pre-treated Advanced Breast Cancer

  Study Details | NCT06997029 | A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors | ClinicalTrials.gov

  • Sponsor

    Bristol-Myers Squibb

  • Trial ID

    NCT06997029

  • Study Url

    https://clinicaltrials.gov/study/NCT06997029?term=NCT06997029&rank=1

  • Cancer Type

    Advanced solid tumors

  • Status

    Recruiting

  Brief Summary

  The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer　

• 

  A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer

  Study Details | NCT07192614 | A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer | ClinicalTrials.gov

  • Sponsor

    AstraZeneca

  • Trial ID

    NCT07192614

  • Study Url

    https://clinicaltrials.gov/study/NCT07192614?term=NCT07192614&rank=1

  • Cancer Type

    Prostate Cancer

  • Status

    Recruiting

  Brief Summary

  This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621. The study is split into different modules which will look at AZD6621 delivered by different methods. The study is also further split into 2 parts, Part A which will test different dose levels of AZD6621 to determine which doses are the best in terms of safety and side effects (dose escalation), and Part B will further test at least two AZD6621 doses in a larger group of participants (dose expansion).

• 

  A Phase 1 First-in-Human, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABBV-711 as a Monotherapy or in Combination With Budigalimab (ABBV-181) in Adult Subjects With Advanced Squamous Tumors

  Study Details | NCT07241039 | A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors | ClinicalTrials.gov

  • Sponsor

    AbbVie

  • Trial ID

    NCT07241039

  • Study Url

    https://kmuh-phase1.com/wp-admin/post-new.php?post_type=clinical-trial-en

  • Cancer Type

    Advanced solid tumors

  • Status

    Recruiting

  Brief Summary

  The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-711 as a monotherapy and in combination with budigalimab (ABBV-181) in adults with advanced squamous tumors.
  
  ABBV-711 is an investigational drug being developed for the treatment of solid tumors. There are multiple treatment arms in this study. Participants will either receive ABBV-711 as a single agent or in combination with budigalimab (another investigational drug) at different doses. Approximately 220 adult participants will be enrolled in the study across 40 sites worldwide.
  
  In part 1, oral ABBV-711 tablets will be given in escalating doses alone to participants with squamous (sq) tumors. In part 2 oral ABBV-711 tablets will be given at a selected dose from part 1 to participants with squamous non-small cell lung cancer (sqNSCLC), or head and neck squamous cell carcinoma (HNSCC). In part 3, oral ABBV-711 tablets will be given in escalating doses in combination with intravenously (IV) infused budigalimab to participants with sq tumors. In part 4 oral ABBV-711 tablets will be given at a selected dose from part 3 in combination with IV infused budigalimab to participants with sqNSCLC, or HNSCC. The estimated duration of the study is up to approximately 5 years.
  

• 

  AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

  Study Details | NCT07222566 | A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | ClinicalTrials.gov

  • Sponsor

    Pfizer

  • Trial ID

    NCT07222566

  • Study Url

    https://clinicaltrials.gov/study/NCT07222566?term=NCT07222566&rank=1

  • Status

    Recruiting

  Brief Summary

  This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body.
  
  Participants in this study will be assigned to two different parts of the study depending on their type of tumor: participants with squamous NSCLC will be assigned to Part 1, while participants with non-squamous NSCLC will be assigned to Part 2.
  
  Part 1 - Arm A or Part 2 - Arm C (Experimental Group): Will receive a new study medicine called PF-08634404 along with a kind of chemotherapy specific to the type of tumor.
  Part 1 - Arm B or Part 2 - Arm D (Control Group): Will receive an approved medicine called pembrolizumab along with a kind of chemotherapy specific to the type of tumor.
  
  Participants will receive their assigned treatment through intravenous (IV) infusions, which means the medicine is given directly into a vein. The treatment will be given in cycles, participants will receive PF-08634404 or Pembrolizumab in combination with chemotherapy followed by maintenance with either PF-08634404 or Pembrolizumab monotherapy (Part 1) or PF-08634404 or Pembrolizumab in combination with a chemotherapeutic drug (Part 2). Participants will continue receiving treatment if it is helping and not experiencing serious side effects.

• 

  A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

  Study Details | NCT07226999 | A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer | ClinicalTrials.gov

  • Sponsor

    Pfizer

  • Trial ID

    NCT07226999

  • Study Url

    https://clinicaltrials.gov/study/NCT07226999?term=NCT07226999&rank=1

  • Cancer Type

    Small cell lung cancer

  • Status

    Preparing

  Brief Summary

  This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has spread widely in the body.

For more information on phase one cancer
clinical trials,get in contact our team

Contact